Add BrightSurf on Google Email

How heart failure disrupts the cell’s powerhouse

Researchers from Hokkaido University have identified a link between succinyl-CoA levels and energy metabolism in heart cells affected by chronic heart failure. Supplementation with 5-aminolevulinate acid improved heart function and oxidative phosphorylation capacity in mice with surgically blocked blood supply.

SourceHokkaido University·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateOct 24, 2022

Detecting Alzheimer’s disease in the blood

Researchers at Hokkaido University have developed a biosensing technology to detect amyloid β build-up in the brain from biomarkers in blood samples. The Digital ICA TM technology can detect Aβ-binding exosomes in mice, increasing with age and disease progression.

SourceHokkaido University·JournalAlzheimer s Research & Therapy·TypeExperimental study·DateOct 6, 2022

Traditoinal medicine could give new hope to heart patients

Researchers from the University of Copenhagen have identified a new mechanism in ARVC that could lead to a potential treatment strategy. They found that activating sirtuin-3 can slow down disease progression, and honokiol, a natural product extracted from the tulip tree, has been shown to work similarly.

SourceUniversity of Copenhagen - The Faculty of Health and Medical Sciences·JournalCirculation·TypeExperimental study·DateSep 19, 2022

Regulation is the name of the game

A new study by Kyoto University found that Regnase-1 gene expression is low in patients with pulmonary arterial hypertension (PAH), mirroring the pathology of humans. The protein's mRNA degradation leads to PAH inhibition, offering a potential new treatment for heart failure and premature death.

SourceKyoto University·JournalCirculation·TypeExperimental study·DateSep 6, 2022

Old drugs hint at new ways to beat chronic pain

A newly identified link between chronic pain and lung cancer in mice suggests that old drugs such as clonidine, capsaicin, and fluphenazine may offer new treatments for chronic pain. The study found that blocking the BH4 pathway reduced pain sensitivity and decreased tumor growth in mouse models of KRAS-driven lung cancer.

SourceIMBA- Institute of Molecular Biotechnology of the Austrian Academy of Sciences·JournalScience Translational Medicine·TypeExperimental study·DateAug 31, 2022

Scientists find molecular clues behind acute and chronic phases of traumatic brain injury

Researchers at Arizona State University have discovered molecular signatures associated with acute and chronic phases of traumatic brain injury (TBI). The study aims to address current limitations in TBI diagnosis and treatment by identifying biomarkers and understanding the blood-brain barrier's role in drug delivery.

SourceArizona State University·JournalScience Advances·TypeExperimental study·DateJul 22, 2022

p53 in liver cancer: The ultimate betrayal?

A study published in Cancer Research found that constitutively activated p53 in hepatocytes of chronic liver disease patients creates a microenvironment supportive of tumor formation from hepatic progenitor cells. This novel mechanism challenges the traditional role of p53 as a cancer suppressor.

SourceOsaka University·JournalCancer Research·TypeExperimental study·DateJul 12, 2022

Molecular pathway by which stress affects lupus discovered

Researchers at Hokkaido University have discovered a molecular pathway by which stress affects lupus, revealing a potential target for treatment. The study found that sleep deprivation caused the activation of microglial cells in the brain, leading to increased levels of IL12 and IL23, a diagnostic marker for neuropsychiatric SLE.

SourceHokkaido University·JournalAnnals of the Rheumatic Diseases·TypeExperimental study·DateJul 11, 2022

Researchers identify cells causing neuronal death in a mitochondrial disease animal model

In a new study, researchers found that microglia cells are responsible for neuronal death in a mitochondrial disease mouse model. Suppressing these cells with the drug Pexidartinib increased life expectancy and reduced motor problems. Further research is needed to understand the specific process by which microglia attack neurons.

SourceUniversitat Autonoma de Barcelona·JournalGlia·TypeExperimental study·DateJul 8, 2022

Greater understanding of immune signalling molecule raises hope for improved clinical use

A detailed understanding of interleukin 2's role in the immune system has been gained through a new mouse model, enabling scientists to identify potential new uses as an immune-modulating biologic drug. This breakthrough may lead to optimized autoimmune and cancer treatment while avoiding unwanted side effects.

SourceBabraham Institute·JournalJournal of Experimental Medicine·TypeExperimental study·DateJun 14, 2022

Rapamycin increases Alzheimer’s-associated plaques in mice, study finds

Researchers at UT Health San Antonio found that rapamycin causes an increase in beta-amyloid protein plaques in mouse models, contradicting its potential benefits. However, a novel method to decrease plaques was discovered by deleting the Tsc1 gene from microglia, leading to increased Trem2 levels and decreased plaques.

SourceUniversity of Texas Health Science Center at San Antonio·JournalJNeurosci·TypeExperimental study·DateJun 7, 2022

Color-changing mouse model allows researchers to non-invasively study deep tissues

Scientists create genetically engineered mouse model that changes color in response to light, allowing them to isolate background noise from blood flow and enhance imaging techniques. This breakthrough enables researchers to observe internal physiology with unprecedented accuracy, paving the way for new treatments and therapies.

SourceDuke University·JournalNature Communications·TypeExperimental study·DateJun 6, 2022

Study finds nanomedicine targeting lymph nodes key to triple negative breast cancer treatment

Researchers found that targeting both tumor and lymph node microenvironments with nanomedicine improves treatment response for metastatic triple negative breast cancer. Long-term tumor remission was achieved in mice models using nanoparticles to deliver immune-modulating drugs.

SourceMichigan Medicine - University of Michigan·JournalScience Translational Medicine·TypeExperimental study·DateMay 12, 2022

Stopping lung damage before it turns deadly

Researchers found that hypoxia can activate immune cells called ILC2s, which respond to harmless environmental allergens and drive mucus production and inflammation in the lungs. The study identifies adrenomedullin as a new target for treating inflammatory and allergic lung diseases.

SourceLa Jolla Institute for Immunology·JournalJournal of Experimental Medicine·TypeExperimental study·DateMay 9, 2022

Brain metastasis looking back in the mirror

Researchers created patient-derived models of brain metastases that recapitulate human disseminated disease, reflecting clinical manifestations and biological characteristics. These models can be used to test therapeutic value of different treatments and explore new approaches tailored to each patient.

SourceInstituto de Medicina Molecular·JournalCell Reports Medicine·TypeExperimental study·DateMay 3, 2022

Does autism begin in the womb?

A study led by Kobe University researchers found that idiopathic autism is caused by epigenetic abnormalities in hematopoietic cells, leading to immune dysregulation and brain-gut axis disorders. The study used BTBR mice as a model and identified histone deacetylase HDAC1 as a common mechanism underlying these pathologies.

SourceKobe University·JournalMolecular Psychiatry·TypeExperimental study·DateMay 1, 2022

Zeroing in on a new treatment for autism and epilepsy

Scientists at Gladstone Institutes have discovered that reducing protein tau levels soon after birth can prevent autism and epilepsy in an experimental model. The study pinpointed the crucial brain cells where tau levels must be reduced to avoid these problems, and showed that lowering tau is still effective when initiated after birth.

SourceGladstone Institutes·JournalScience Translational Medicine·DateApr 27, 2022

Where the mind is without fear: Scientists discover mechanism behind the chemically induced suppression of fearful memories

Researchers at Tokyo University of Science identify brain regions and signaling pathways involved in fear extinction via delta receptor activation. The study suggests a potential therapeutic agent for post-traumatic stress disorders by suppressing fearful memories.

SourceTokyo University of Science·JournalFrontiers in Behavioral Neuroscience·TypeExperimental study·DateApr 25, 2022

Providing a potential treatment option to infants where there is none

A study led by MUSC researchers found that inhibiting the complement system with CR2Crry can prevent long-term brain damage and improve outcomes in premature infants with germinal matrix hemorrhage. The treatment has shown improved survival, weight gain, reduced brain injury, and enhanced motor and cognitive performances.

SourceMedical University of South Carolina·JournalInternational Journal of Molecular Sciences·DateApr 20, 2022

Coughing mice and the fight against pertussis

A team of researchers from Osaka University successfully established a mouse model that can reproduce the severe and persistent cough of pertussis. They found that pertussis toxin, Vag8, and lipooligosaccharide are key bacterial factors involved in inducing coughing, which ultimately leads to bradykinin and TRPV1 signaling.

SourceOsaka University·JournalmBio·TypeExperimental study·DateMar 31, 2022

Penn-Developed CAR T Cells Suppress GI Solid Tumor Cells, Without Toxicity to Healthy Tissue, in Preclinical Research

Researchers at Penn Medicine have discovered a new approach to treat solid cancers using CDH17CAR T cells, which selectively target and eliminate gastrointestinal (GI) solid tumors like gastric, pancreatic, and colorectal cancers in preclinical models. Unlike other immunotherapies, CDH17CAR T cells do not show toxicity to healthy tissues.

New tests and treatments developed in mice for pulmonary fibrosis

Scientists at University of Illinois and Mie University develop monoclonal antibodies to prevent lung cell death in mouse models of idiopathic pulmonary fibrosis and acute respiratory disease syndrome. Non-invasive diagnostic tools also presented could aid in predicting disease progression and identifying patients at risk.